CLNO, PWRM, ENMD, SIRO, MGIC, UNIS Stock Market Report from Stock.PR.com

FREE Daily Stock Alerts From Stock-PR.com

There are many ways to convert biomass fuel into a useable source of energy, one method is biomass gasification. Gasification is thermal process, where heating the biomass in a low oxygen environment generates a gas mixture called syngas or synthesis gas. This gas is made up of mainly hydrogen and carbon monoxide. Depending on the efficiency of the gasification process used, a very clean gas can be produced. This gas can be used for several purposes, even in a one too one ratio in internal combustion engines as was done heavily in world war 2.

Cleantech Transit Inc. is pleased to provide additional details after achieving success on the 500 KW facility and successfully moving past the interconnection testing stage.

Coming on the recent success at the 500KW facility in Merced, California this poises Phoenix Energy to become a leading developer of renewable biomass distributed generation plants that utilize local resources for local energy.

Currently there are two additional projects being pre-certified by Phoenix Energy in California. The projects are each projected to be 1 MW biomass gasification facilities that will provide both electricity and process heat energy. Each facility will provide enough electricity to power approximately 800 homes as well as process heat to be used in drying agricultural products. The projects are expected to complete by the end of 2012.

Cleantech will be providing details on the expecting closing date of its initial investment into Phoenix Energy in the coming weeks.

Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project can generate shareholder returns as well benefit the Company’s manufacturing clients worldwide.

Please visit Cleantech Transit, Inc. website www.cleantechtransitinc.com.

********

Power3 Medical Products, Inc. (PWRM) strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies.

NuroPro Blood Test of Power3 Medical Products, Inc is diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system.

The NuroPro Blood Test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease. Early detection of these diseases would allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.

Parkinson’s disease is one of a larger group of neurological conditions called motor system disorders. Historians have found evidence of the disease as far back as 5000 B.C. It was first described as “the shaking palsy” in 1817 by British doctor James Parkinson. Because of Parkinson’s early work in identifying symptoms, the disease came to bear his name.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials.

To know more information about Power3 Medical Products, Inc., please visit http://www.power3medical.com.

********

EntreMed, Inc. (Nasdaq:ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer recently announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.

The data were presented by the principal investigator for the study, Dr. Ursula A. Matulonis, medical director of gynecologic oncology at Dana-Farber Cancer Institute and associate professor of medicine, Harvard Medical School, during a poster discussion session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2011 in Chicago, Illinois.

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase I clinical trials in solid tumor cancers, leukemia, and multiple myeloma. While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound’s applicability in other forms of cancer.

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia. Additional information about EntreMed is available on the Company’s web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

********

Sirona Dental Systems Inc. (Nasdaq:SIRO) recently announced a public secondary offering by Sirona Holdings Luxco S.C.A (”Luxco”) of its remaining 9,747,480 shares of its common stock and 400,000 shares by Jeffrey T. Slovin, Sirona`s President and a member of its board of directors. Sirona will not receive any of the proceeds from the sale of shares of common stock by the selling stockholders in this offering. The offering will be made under a shelf registration statement filed with the U.S. Securities and Exchange Commission. Barclays Capital Inc. will be the sole underwriter of the offering.

Sirona Dental Systems, Inc., together with its subsidiaries, manufactures and sells dental equipment for dentists worldwide.

********

Magic Software Enterprises Ltd. (Nasdaq:MGIC) recently announced its financial results for the first quarter of 2011. Financial Highlights for the First Quarter: First quarter revenues increased 29% year over year to $25.5 million from $19.7 million. Operating income for the first quarter increased 78% year over year to $3.1 million, compared to $1.8 million in the same period last year. Net income for the first quarter increased 68% year over year to $3.1 million from $1.9 million in the same period last year. Operating cash flow for the quarter amounted to $4.8 million. Total cash and cash equivalents, short-term bank deposits and short-term investments in marketable securities as of March 31, 2011 amounted to $50.2 million.

Magic Software Enterprises Ltd. develops, markets, and supports software development and deployment technology, and applications. It offers uniPaaS, an application platform for software development and deployment; and iBOLT, a platform for business integration and business process management.

********

Unilife Corporation (Nasdaq:UNIS) recently announced that it intends to release its financial results for the fiscal 2011 third quarter ended March 31, 2011 after market trading ends on Monday, May 16, 2011. Management has scheduled a conference call for 4:30 p.m. U.S. Eastern Daylight Time on May 16, 2011 (Tuesday, May 17 at 6:30 a.m. AEST), to review the Company’s financial results, market trends, and future outlook. The conference call will be broadcast over the Internet as a “live” listen only webcast. To listen, please go to: http://ir.unilife.com/events.cfm. Listeners are urged to login approximately 20 minutes before the conference call is scheduled to begin in order to register, as well as download and install any necessary audio software.

Unilife Corporation, a medical device company, focuses on the design, development, manufacture, and supply of a proprietary range of retractable syringes in the United States and internationally. Its syringes incorporate automatic and integrated safety features to protect those at risk of needlestick injuries and other unsafe injection practices.

**********************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer). Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) anticipates receiving 5,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services for Cleantech Transit, Inc. (CLNO.OB) Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

**********************************************************

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

**********************************************************

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.